Highlights

  • 05 Jun 2014
    - Highlights

    EBE comments on quality guideline (EMA/CHMP/BWP/247713/2012)

    In June 2014, EMA published the final version of the Quality guidelines, following approval by Committee for Medicinal Products for Human Use (CHMP) at the end of May 2014.

     14 stakeholders submitted comments. European Biopharmaceutical Enterprises (EBE), stakeholder No 5, of a total of 43 comments, 25 were accepted / partly accepted / acknowledged, while some 18 were not accepted.

    Read more | Download Document (140.29 kB)
  • 02 Apr 2014
    - Highlights

    Biopharmaceutical SMEs convene to discuss funding strategies

    Last week, on 27 March 2014, 65 SMEs and stakeholders in Biopharmaceutical Innovation met to discuss public funding strategies for small companies at a workshop in Brussels organised by European Biopharmaceutical Enterprises, EBE, and European Biotechnology Network, EBN, two organisations that support SME-driven life science development.
    Read more | Download Document (185.97 kB)
  • 27 Sep 2013
    - Highlights

    EMA - European Medicines Agency organising workshop on biosimilars

    The European Medicines Agency is holding a workshop on biosimilars on 31 October 2013 in London.

    The Agency is organising this workshop as part of its public-consultation exercise on its three draft revised overarching guidelines on biosimilars.

    Read more |
  • 15 Aug 2013
    - Highlights

    World health report 2013: Research for universal health coverage

    The main purpose of the report is to provide countries, donor agencies, international organizations and others with the information they need to help them make policy and funding decisions. The report is also offered to a wider audience, from universities, teaching hospitals and schools, to journalists and the public at large - anyone, in fact, with a professional or personal interest in international health issues.
    Read more |